All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy
Stifel Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $80
Stifel analyst Dae Gon Ha maintains $Intellia Therapeutics(NTLA.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 37.7% and
Stifel Nicolaus Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
The Past Three Years for Intellia Therapeutics (NASDAQ:NTLA) Investors Has Not Been Profitable
Every investor on earth makes bad calls sometimes. But really big losses can really drag down an overall portfolio. So spare a thought for the long term shareholders of Intellia Therapeutics, Inc. (
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
On Wednesday, Cathie Wood-led Ark Invest made a notable move by offloading a significant number of shares in Tesla Inc (NASDAQ:TSLA), despite the recent rally driven by the company's impressive second
Intellia Therapeutics(NTLA.US) Officer Sells US$9,286.65 in Common Stock
$Intellia Therapeutics(NTLA.US)$ Officer Clark Eliana sold 405 shares of common stock on Jul 1, 2024 at an average price of $22.93 for a total value of $9,286.65.Source: Announcement What is statement
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
On Tuesday, Cathie Wood-led Ark Invest made significant adjustments to its portfolio, offloading a substantial number of shares in Tesla Inc (NASDAQ:TSLA) and scooping up a hefty stake in Palantir Tec
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $73 price target.
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $24 to $73
On Jun 27, major Wall Street analysts update their ratings for $Intellia Therapeutics(NTLA.US)$, with price targets ranging from $24 to $73.BMO Capital analyst Kostas Biliouris maintains with a buy ra
Cathie Wood's Ark Invest Acquires $7.3M Worth Of Shares In This Promising Netflix Competitor, Sells Off Coinbase Stock Amid Bitcoin Slump
On Wednesday, Cathie Wood-led Ark Invest made significant trades in Roku Inc (NASDAQ:ROKU) and Coinbase Global Inc (NASDAQ:COIN), amidst a volatile market. These prominent trades were part of a series
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $29 to $95
On Jun 26, major Wall Street analysts update their ratings for $Intellia Therapeutics(NTLA.US)$, with price targets ranging from $29 to $95.Citi analyst David Lebovitz maintains with a hold rating, an
Intellia Therapeutics: Dulac Recently Served as CFO of Fate Therapeutics >NTLA
Intellia Therapeutics: Dulac Recently Served as CFO of Fate Therapeutics >NTLA
Express News | Intellia Therapeutics Inc - Glenn Goddard to Step Down as CFO Effective June 30, 2024
Express News | Intellia Therapeutics Inc - Appoints Edward Dulac as CFO Effective July 22, 2024
Express News | Intellia Therapeutics Announces CFO Transition
Intellia Therapeutics Presents Data On Redosing With In Vivo CRISPR Therapy; 55 Mg NTLA-2001 Dose Shows 90% Median Reduction In Serum TTR At Day 28; Well Tolerated Across All Patients; Potential Redosing Advantage For Future Therapies
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28
Express News | Intellia Therapeutics Inc: 55 Mg Follow-on Dose Was Well Tolerated Across All Patients
Express News | Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy With Its Proprietary Lnp-Based Delivery Platform
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA